2022
A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma
Sun R, Liu Y, Lei C, Tang Z, Lu L. A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma. Biological Procedures Online 2022, 24: 7. PMID: 35751033, PMCID: PMC9233353, DOI: 10.1186/s12575-022-00170-2.Peer-Reviewed Original ResearchCutaneous melanomaLack of therapeutic optionsPrediction of prognosisHigh-risk groupBackgroundThe prognosisMalignancy of cancerTherapeutic optionsTherapeutic responseClinical factorsPrognosisCellular proliferationClinical practicePatientsPI3K/AKT/mTOR pathwayTCGA databaseMelanomaUp-regulatedFunctional analysisPotential drug targetsMolecular mechanismsBioinformatic evidenceDrug targetsRNA splicingDownregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, Sun R, Liu J, Xiao Q, Li Y, Lu P, Peng Y, Peng Y, Shu G, Yin G. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduction And Targeted Therapy 2022, 7: 87. PMID: 35351858, PMCID: PMC8964798, DOI: 10.1038/s41392-022-00902-6.Peer-Reviewed Original ResearchConceptsOxaliplatin resistanceColorectal cancerTumor growthMEIS1 expressionCell sensitivity to oxaliplatinPreventing DNA damage repairCombination of oxaliplatinSurvival of CRC patientsTreatment of colorectal cancerSensitivity to oxaliplatinEZH2 inhibitor GSK126Suppressed tumor growthReverse oxaliplatin resistanceFrontline treatmentAcquired resistanceCRC patientsInhibitor GSK126OxaliplatinFEN1 expressionTherapeutic strategiesDNA damage repairELFN1-AS1Cell survivalMeis1Patients
2019
Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review
Sun R, Wang R, Chang S, Li K, Sun R, Wang M, Li Z. Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review. Frontiers In Pharmacology 2019, 10: 1457. PMID: 31920650, PMCID: PMC6930187, DOI: 10.3389/fphar.2019.01457.Peer-Reviewed Original ResearchLong non-coding RNAsNon-small cell lung cancerNon-coding RNAsDrug resistance of non-small cell lung cancerCell lung cancerDrug resistanceResistance of non-small cell lung cancerLung cancerDevelopment of drug resistancePrognosis of patientsProgress of drug therapyLung cancer casesLncRNAsPoor prognosisCancer casesDrug therapyCancerCancer mortalityPrognosisDrugPatientsLungMini review